- Home
- JBDI vs BRTX Comparison
JBDI vs BRTX Comparison
Compare JBDI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- BRTX
- Stock Information
- Founded
- JBDI 1983
- BRTX 1997
- Country
- JBDI Singapore
- BRTX United States
- Employees
- JBDI N/A
- BRTX N/A
- Industry
- JBDI
- BRTX Managed Health Care
- Sector
- JBDI
- BRTX Health Care
- Exchange
- JBDI Nasdaq
- BRTX Nasdaq
- Market Cap
- JBDI 14.0M
- BRTX 15.9M
- IPO Year
- JBDI 2024
- BRTX N/A
- Fundamental
- Price
- JBDI $0.68
- BRTX $1.80
- Analyst Decision
- JBDI
- BRTX Strong Buy
- Analyst Count
- JBDI 0
- BRTX 1
- Target Price
- JBDI N/A
- BRTX $18.00
- AVG Volume (30 Days)
- JBDI 431.8K
- BRTX 812.7K
- Earning Date
- JBDI 02-15-2025
- BRTX 03-28-2025
- Dividend Yield
- JBDI N/A
- BRTX N/A
- EPS Growth
- JBDI N/A
- BRTX N/A
- EPS
- JBDI N/A
- BRTX N/A
- Revenue
- JBDI $9,394,000.00
- BRTX $377,000.00
- Revenue This Year
- JBDI N/A
- BRTX $482.76
- Revenue Next Year
- JBDI N/A
- BRTX $212.24
- P/E Ratio
- JBDI N/A
- BRTX N/A
- Revenue Growth
- JBDI N/A
- BRTX 189.55
- 52 Week Low
- JBDI $0.51
- BRTX $1.03
- 52 Week High
- JBDI $39.41
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- JBDI N/A
- BRTX 37.55
- Support Level
- JBDI N/A
- BRTX $2.26
- Resistance Level
- JBDI N/A
- BRTX $2.38
- Average True Range (ATR)
- JBDI 0.00
- BRTX 0.22
- MACD
- JBDI 0.00
- BRTX -0.09
- Stochastic Oscillator
- JBDI 0.00
- BRTX 7.98
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.